The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors

Zheng Zhang1,*, Rainer B Lanz1,*, Lijuan Xiao2,*, Lei Wang1, Sean M Hartig1, Michael M Ittmann3, Qin Feng1, Bin He1,2

1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA
2Department of Medicine-Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA
3Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA

*These authors contributed equally to this work

Correspondence to: Bin He, email: bhe@bcm.edu
Qin Feng, email: qfeng@bcm.edu

Keywords: prostate cancer, ERG, miR-200, miR-205

Received: March 13, 2016  Accepted: April 27, 2016  Published: May 13, 2016

ABSTRACT

The TMPRSS2-ERG fusion occurs in approximately 50% of prostate cancer (PCa), resulting in expression of the oncogenic ERG in the prostate. Because ERG is a transcriptional activator, we hypothesized that ERG-regulated genes contribute to PCa development. Since microRNA (miRNA) has crucial functions in cancer, we searched for miRNAs regulated by ERG in PCas. We mined published datasets based on the MSKCC Prostate Oncogene Project, in which a comprehensive analysis defined the miRNA transcriptomes in 113 PCas. We retrieved the miRNA expression datasets, and identified miRNAs differentially expressed between ERG-positive and ERG-negative samples. Out of 369 miRNAs, miR-200a, -200b, -429 and -205 are the only miRNAs significantly increased in ERG-positive tumors. Strikingly, miR-200a, -200b and -429 are transcribed as a single polycistronic transcript, suggesting they are regulated at the transcriptional level. With ChIP-qPCR and in vitro binding assay, we identified two functional ETS motifs in the miR-200b/a/429 gene promoter. Knockdown of ERG in PCa cells reduced expression of these three miRNAs. In agreement with the well-established tumor suppressor function, overexpression of the miR-200b/a/429 gene inhibited PCa cell growth and invasion. In summary, our study reveals that miR-200b/a/429 is an ERG target gene, which implicates an important role in TMPRSS2/ERG-dependent PCa development. Although induction of the tumor suppressive miR-200b subfamily by oncogenic ERG appears to be counterintuitive, it is consistent with the observation that the vast majority of primary prostate cancers are slow-growing and indolent.

INTRODUCTION

miRNAs are small non-coding endogenous RNAs of approximately 22 nucleotides that regulate gene expression by directing their target mRNAs for degradation and/or translational repression. miRNAs are pleiotropic modulators in all important biological processes, including development, differentiation, immunity, heart disease, and cancer. In cancer, miRNAs can regulate tumor initiation and progression, and factors involved in miRNA biogenesis are frequently dysregulated. Certain miRNAs function as oncogenes (oncomiR). For instance, miR-21 is overexpressed in most tumor types [1] where it downregulates the tumor suppressor PDCD4 [2, 3]. The oncogenic miR-17-99 cluster is located at 13q31, which is frequently amplified in solid tumors and in lymphomas [4, 5]. The expression of the miR-17-99 cluster is induced by oncogenic c-Myc [6]. miR-155 is another oncomiR highly expressed in Hodgkin’s lymphomas and B cell lymphomas [7, 8]. miRNAs can also function as tumor suppressors [9, 10]. The miR-15a/16-1 cluster at 13q14.3 is frequently deleted in B-cell chronic lymphocytic leukemia (B-CLL) [10], and miR-15a and miR-16-1 are bona fide tumor suppressors, which act by targeting oncogene Bcl-2 [11].
The miR-34 family, which consists of miR-34a, b and c, is induced by p53 and functions as a key regulator of tumor suppression [12–16]. The Let-7 family of miRNAs inhibits tumor growth and metastasis by targeting the oncogenes H-Ras, HMGA2 and c-Myc [17–19].

Another family of well-established tumor suppressive miRNAs is miR-200, consisting of miR-200a, -200b, -200c, -141, and -429, which are clustered at two genomic locations. In the human genome, miR-200b, -200a, and -429 are located on chromosome 1 and transcribed by RNA Polymerase II as a single long primary miRNA transcript [20], while miR-200c and -141 are clustered on chromosome 12. The miR-200 family inhibits cancer cell invasion and metastasis by suppressing epithelial-mesenchymal transition through targeting ZEB1 and ZEB2 [21–24]. Genome-wide analysis of miR-200 targets in living cells has confirmed that miR-200 prevents cell migration and invasion through a coordinate control of actin cytoskeleton dynamics [25]. In addition, miR-200 family members can block tumor angiogenesis by targeting interleukin-8 and CXCL1 [26]. In agreement with its tumor suppressor role, the expression of miR-200 family members has been associated with favorable clinical outcome in many cancers [27–29].

In contrast to other well-characterized oncomiRs and tumor suppressors, the role of some miRNAs in cancer is controversial and context-dependent. For instance, miR-205 is highly enriched in progenitor cells in the mammary gland and prostate, and has a function in stem cell maintenance [30–32]. miR-205 is oncogenic in the mammary gland by targeting the tumor suppressor PTEN [30]. On the other hand, miR-205 can also inhibit tumor invasion by targeting ZEB1 and ZEB2 [21]. miR-205 expression levels were significantly lower in prostate cancer than in normal prostate, suggesting a tumor suppressor function [33]. However, in normal prostate, miR-205 is preferentially expressed in basal epithelial cells [31]. As a result, reduced miR-205 expression in human prostate cancer is probably caused by the loss of basal cells, instead of being lost in luminal cells as a tumor suppressor.

In prostate cancers, TMPRSS2-ERG fusion caused by chromosomal translocation is present in approximately 50% of samples and manifests over-expression of a functional ERG transcription factor [34]. ERG modulates AR signaling in VCaP cells [35, 36] and the murine prostate gland [37], and therefore contributes to prostate cancer progression. TMPRSS2/ERG also cooperates with Pten loss to promote prostate oncogenesis in mouse models [38, 39]. However, how ERG controls prostate tumorigenesis and progression remains largely unknown.

ERG is a member of the erythroblast transformation-specific (ETS) family of transcription factors. It contains a highly conserved DNA binding ETS domain, which binds to DNA elements with a central GGAA motif. We reasoned that, as a transcriptional activator, ERG protein per se might not directly control cancer development. Instead, the downstream target genes regulated by ERG could determine prostate cancer initiation and progression. In a search for ERG target genes, we used recently published genomic profiling of human prostate cancer [40], in which a comprehensive analysis was applied to define miRNA transcriptomes in 113 prostate tumors. We retrieved the miRNA expression data sets, divided them based on ERG expression levels, and looked for miRNAs differentially expressed between ERG-positive and ERG-negative samples. Strikingly we found that miR-200a, b, -429, and -205 are the only four miRNAs significantly increased in ERG-positive tumors. In this study, we provide definitive evidence that the miR-200b/a/429 subfamily is an ERG target gene in human prostate cancers.

RESULTS

Identification of ERG-associated miRNAs in human prostate cancers

Because ERG is a transcription activator and miRNAs are emerging as crucial regulators of cancer development, we tested the hypothesis that ERG directly regulates miRNA expression in human prostate cancers. We retrieved published miRNA expression data sets [40], and based on ERG expression levels, we classified the tumor samples into ERG-positive and ER-negative groups. We then looked for miRNAs differentially expressed between ERG-positive and ERG-negative samples. As shown in Figure 1, out of 369 miRNAs, the average expression levels of four miRNAs including miR-200a, miR-200b, miR-429, and miR-205 were significantly higher in ERG-positive human prostate cancer samples. Strikingly, miR-200a, miR-200b and miR-429 are known to be transcribed as a single polycistronic transcript, suggesting that these three miRNAs are regulated by ERG at the transcriptional level.

Identification of ERG binding motifs in the promoter region of miR-200b/a/429 gene cluster

Strong positive association of these four miRNAs with ERG expression suggests that these miRNAs might be directly regulated by ERG at the transcriptional level in human prostate cancers. By taking advantage of published ERG chromatin immunoprecipitation (ChIP-Seq) data sets, we investigated if ERG directly binds to the regulatory regions near the miR-200b/a/429 cluster and miR-205 gene in prostate cancer cells.

Among the commonly used prostate cancer cell lines, VCaP is the only cell line that harbors TMPRSS2/ERG translocation and expresses ERG protein. Two research groups have published genome-wide ERG ChIP-seq analyses in VCaP cells [35, 36]. We retrieved the data
sets from both studies and examined the ERG sites in the mir-200b/a/429 gene cluster and miR-205HG gene using the UCSC genome browser. Shown in Figure 2A, based on ERG ChIP-seq results [36], we nominated an ERG binding peak immediately proximal to the transcription start site (TSS) of mir-200b/a/429 gene cluster (Figure 2A). This ERG binding peak was confirmed by the other ChIP-seq analysis [35] (data not shown). On the other hand, expression of miR-205 is transcribed from its host gene miR-205HG on chromosome 1. Surprisingly, no ERG binding peak was identified within 25 kbp upstream or downstream of the miR-205HG gene.

Within the ERG binding site in the miR-200b/200a/429 gene promoter, we identified two potential ERG binding sequences, ETS-1 and ETS-2 (Figure 2A), that match the canonical ERG binding sequences derived from genome-wide ERG ChIP-seq analyses [41] (Figure 2B). Next we confirmed that ERG indeed binds to this site in VCaP cells by ChIP-qPCR analysis (Figure 2C). To further determine whether these two potential binding sequences ETS-1 and ETS-2 are bona fide ERG binding motifs, we performed an in vitro binding assay. Shown in Figure 2D, 168 bp of miR-200b promoter region containing ETS-1 and ETS-2 was amplified by PCR with biotinylated primers. ETS-1 and ETS-2 were mutated individually or in combination: WT, two both sites intact; M1, ETS-1 mutated; M2, ETS-2 mutated; M1+2, both sites mutated. These DNA fragments were bound to streptavidin agarose beads, and incubated with VCaP total cell lysates, which contain the endogenous ERG proteins. After binding at 4ºC, the agarose beads were precipitated, washed, and bound proteins were denatured and separated by SDS-PAGE gel. The presence of ERG was detected by western blot analysis using anti-ERG antibody. In the right panel of Figure 2D, wild type sequence shows robust ERG protein binding (lane 3). Mutation of ETS-1 dramatically reduced the binding (lane 4) and mutation of ETS-2 moderately reduced the binding (lane 5), while mutation of both sites completely abolished binding (lane 6). This in vitro binding assay demonstrates that the promoter region of miR-200b/200a/429 contains two functional ERG binding motifs which recruit ERG efficiently.

Next, in order to test whether expression levels of miR-200a, miR-200b, miR-429 are regulated by ERG in VCaP cells, we used siRNA to specifically knock down ERG and used qPCR to measure mature miRNA levels.

Figure 1: Scatter representation of miRNA expression levels grouped by the patient’s ERG mRNA expression. Average expression levels of 369 microRNAs plotted for their relationship between ERG-positive (40 patients) and ERG-negative (60 patients) expression, after removal of 13 samples with moderate ERG levels. Log2 values of average expression for ERG positive/negative PCA and p-value for the four miRNAs that are the focus of this study are: miR-200a (10.85/9.49, p = 1.88e-05), miR-200b (11.99/10.51, p = 1.42e-06), miR-205 (11.50/9.84, p = 9.85e-04), miR-429 (9.73/8.22, p = 1.59e-05). miRNA and ERG expression data are from the Memorial Sloan-kettering Cancer Center, New York [40].
As shown in Figure 2E, treatment of VCaP cells with two individual ERG siRNAs (Stealth siRNA, Invitrogen) for four days caused approximately 40% reduction in the expression levels of miR-200b, miR-200a, and miR-429. The expression level of miR-200b/a/429 primary transcript was also significantly reduced after VCaP cells were treated with ERG siRNA for three days (Figure 2F). Taken together, our results indicate that miR-200b, miR-200a, and miR-429 are directly and positively regulated by ERG at the transcriptional level in VCaP cells. The remaining expression of miR-200b subfamily in VCaP cells after ERG knockdown is in agreement with a previous report that SP1 controls the basal epithelial expression of miR-200b subfamily [20]. On the other hand, expression of miR-205 was undetectable in VCaP cells by qPCR. Therefore, we cannot determine whether miR-205 is regulated by ERG in prostate cancer cells.

Effects of miR-200b/a/429 cluster and miR-205 on prostate cancer growth and migration

The roles of miRNA-200 family and miR-205 have been studied in many cancer types. However, their roles in human prostate cancers are relatively unknown. We first measured the expression levels of these miRNAs in commonly used human prostate cancer cell lines by

---

**Figure 2: Regulation of miR-200b/200a/429 cluster gene expression by ERG at the transcriptional level.** (A) ERG ChIP-seq data sets were retrieved, including GSM717395, GSM717397, GSM717392, and GSM717394. ERG binding peaks were viewed by UCSC genome browser. *In silico* analysis reveals two classical ERG binding elements (Ets) in the promoter region. TSS, transcription start site. (B) Diagram of consensus ERG-binding sequence derived from genome-wide ChIP-seq analyses. (C) Confirmation of ERG binding to the promoter of miR-200b/a/429 gene by individual ChIP-qPCR analysis. VCaP cells were treated with negative control siRNA or ERG siRNA for three days before being fixed for ChIP assay. The purified ChIP DNA was used in qPCR to amplify a region in a gene desert (Active Motif, cat No. 71001) and miR-200b promoter region. Data are presented as fold changes of ERG enrichment over IgG enrichment. (D) *In vitro* binding of ERG protein to wild type, but not mutant miR-200b/a/429 promoter region. “X” in blue stands for deletion of the corresponding nucleotide. (E) Reduced miR-200b, miR-200a, and miR-429 expression levels in VCaP cells after being treated with two individual ERG siRNAs (stealth siRNA, Invitrogen) for four days. Error bars, mean ± SEM. *P < 0.05. (F) Reduced miR-200b/a/429 primary transcript levels in VCaP cells after being treated with ERG siRNA for three days. Error bars, mean ± SEM. *P < 0.05. Western blot analysis was performed to confirm efficient ERG knockdown.
sequences. We obtained ERG transgenic mice from the Jackson Laboratory [42], and dissected the prostate lobes, including anterior, ventral, and dorsal-lateral lobes. In Figure 4, ERG expression was robust in all the lobes in ERG transgenic mice, but not in wild type control litter mates. However, the expression levels of miR-200b, miR-200a, miR-429, and miR-205 in transgenic mice are similar to that of wild type litter mates, indicating that ERG cannot induce the expression of these four miRNAs in murine prostate. This is probably due to the lack of ERG binding motifs in the promoter region of murine mir-200b/a/429 gene (data not shown).

**DISCUSSION**

In this study, we found that, out of 369 miRNAs, the expression levels of four miRNAs, including three members of the miR-200b subfamily and miR-205, are positively associated with ERG expression in MSKCC prostate cancer data sets. Interestingly, in a previous report, miR-200c is found to be an ERG target gene in VCaP cells and miR-200c expression is actually negatively regulated by ERG [43, 44]. Although there is no association between miR-200c and ERG expression levels in the MSKCC cohort of human prostate tumor samples based on our analysis, we cannot rule out the possibility that miR-200c expression might be inversely correlated with ERG expression in different cohorts of human prostate cancer samples and thus has a role in TMPRSS2/ERG-dependent prostate cancer development.

A quite surprising finding is that miR-205 expression is positively correlated with ERG, however, the underlying mechanism is unknown. ChiP-seq analyses reveal no ERG binding site near the miR-205 host gene (+/− 25 kbp) in VCaP cells. We cannot rule out the possibility that ERG might regulate miR-205HG transcription by a long distance looping mechanism, or a transcription factor regulated by ERG regulates miR-205 expression. However, the expression of ERG and miR-205 is mutually exclusive in cultured prostate cancer cells (Figure 3A). Additionally in prostate tissue, miR-205 is regulated by TP63 [45] and highly enriched in the basal epithelial cells of the prostate [31], while TMPRSS2 promoter-driven ERG is expressed in the luminal epithelial cells. Therefore miR-205 and ERG are expressed in different cell compartments in the prostate. The mutual exclusive expression pattern suggests that association of ERG and miR-205 in human prostate cancers might be through an indirect mechanism. Because basal epithelial cells are lost during prostate cancer development, it is possible that TMPRSS2/ERG-dependent prostate tumors retain more basal cells, resulting in high levels of miR-205 in the tumors. This possibility remains to be investigated.

One exciting finding of our study is that ERG directly up-regulates the tumor suppressive miR-200b subfamily of miRNAs in prostate cancer. Although the miR-200 family of miRNAs can also be regulated at post-transcriptional levels [46], our evidence indicate that ERG can directly bind to miR-200b/a/429 promoter to facilitate its transcription in prostate cancer cells. High levels of miR-200
Figure 3: Role of miR-200b subfamily and miR-205 on prostate cancer proliferation and invasion. (A) Expression levels of miR-200a, miR-200b, miR-429, miR-205, and ERG in commonly used prostate cancer cell lines, including LNCaP, VCaP, 22RV1, PC3, DU145. Mature miRNAs expression levels were measured by qRT-PCR, normalized against RNU48 internal control. (B) Expression of miRNAs in PC3 stable cell lines, including PC3-vec, PC3-miR-200b/a/429, PC3-miR-205, and PC3-miR-200b/a/429/205. (C) The effect of miRNAs on PC3 cell growth as determined by MTT assay. (D) PC3 stable cell Matrigel invasion assay using BD Biocoat Matrigel Invasion Chambers. Representative pictures of invaded cells stained with crystal violet. Four stable cell lines, PC3-vec, PC3-miR-200b/a/429, PC3-miR-205, and PC3-miR-200b/a/429/205. (E) Quantification of invasion. Invaded cells were stained with crystal violet, which was then solubilized in 1% SDS. The absorbance was measured at 595 nm. Error bars, mean ± SEM. *P < 0.05.

Figure 4: miR-200b/200a/429 subfamily and miR-205 are not induced by ERG in the prostate of Pbsn-ERG transgenic mice. Anterior (AP), dorsal-lateral (DLP), and ventral (VP) prostate lobes were harvested from wild type litter mates (n = 3) and Pb-ERG transgenic mice (n = 2). Real-time qPCR was used to determine expression levels of human ERG, and mouse miR-200b, miR-200a, miR-429 and miR-205. Error bars, mean ± SEM.
MATERIALS AND METHODS

Cell culture and transient transfection

Human prostate cancer cell lines were obtained from the ATCC via the Tissue Culture Core at the Baylor College of Medicine, and cultured in appropriate media in a 5% CO2 incubator at 37°C. Specifically VCaP cells were cultured in DMEM high glucose (Life Technologies) supplemented with 10% FBS and 1 nM R1881. LAPC4 cells were cultured in IMDM (Life Technologies) with 10% FBS, 1 nM R1881, and 1× Glutamax (Thermo Fisher Scientific). LNCaP and 22RV1 cells cultured in RPMI1640 (Life Technologies) with 10% FBS. PC3 cells were cultured in DMEM/F12 (Life Technologies) with 10% FBS. DU145 cells were cultured in DMEM high glucose (Life Technologies) with 10% FBS. Cell cultures are discarded after 3 months or 15 passages and replenished from frozen stocks. Cells were regularly tested for mycoplasma contamination. Individual Silencer siRNAs against ERG were purchased from Thermo Fisher Scientific. 50 nM of siRNA in Opti-MEM were transiently transfected into cells using Lipofectamine RNAiMAX (Thermo Fisher Scientific), following the reverse transfection protocol. Cells were harvested four days after transfection for real time qPCR analyses. To measure the expression level of miR-200b/a/429 primary transcript after ERG knockdown, VCaP cells were transiently transfected with 50 nM of ERG siRNAs. Cells were harvested three days later for RNA purification. Total RNA was reverse transcribed using high capacity RNA-to-cDNA kit (ThermoFisher, cat. No. 4387406) and primary transcript of miR-200b/a/429 was determined by real-time qPCR using TaqMan Pri-miRNA assay and normalized against total RNA (ThermoFisher, cat. No. Hs03303027_pr).

Plasmid

To construct a lentiviral vector for the simultaneous expression of miR-200b, miR-200a and miR-429 in mammalian cells, 2310 bp of human miR-200b/a/429 genomic DNA was amplified by PCR and cloned into EcoRI/BamHI site of the pCDH-CMV-MCS-Puro vector (System Biosciences, Mountain View, CA, USA), resulting in pCD-HmiR-200b/a/429. The sequences of two PCR primers are: 5′-CCA GGT GAA TCC CAG GAC CCA AAG CTG GTG-3′, and 5′-ACT GCC GGA TCC GAG GTG CGG GCA CAA GAG-3′. To construct a lentiviral vector for the expression of miR-205 in mammalian cells, 410 bp of human miR-205 genomic DNA was amplified by PCR and cloned into EcoRI/BamHI site of the pCDH-CMV-MCS-Puro, resulting in pCDH-miR-205. The sequences of two PCR primers are: 5′-CCA GGT GAA TCC CAG GAC CCA AAG CTG GTG-3′, and 5′-ACT GCC GGA TCC GAG GTG CGG GCA CAA GAG-3′.

predic
TTC TCT CCC AAA TGT GTG ATT CC-3'; and 5'-CCA TCT GGA TCC TCT TTT CCA ATG TGC CCA TC-3'. To express all four miRNAs, 410 bp of human miR-205 genomic DNA was amplified by PCR and cloned into BamHI/NcoI site of the pCDH-miR-200b/a-429 vector, resulting in pCDH-miR-200b/a-429/205. The sequences of PCR primers are: 5'-CCA GGT GGA TCC TCT CCA AAA TGT GTG ATT CC-3'; and 5'-CCA TCT GCG GCC GCT TTT TCC AAT CTG CCC ATC-3'. 168 bp of miR-200b/a-429 promoter region that contains ETS-1 and ETS-2 was amplified by PCR and cloned into Acc65I/Xhol site of pGL3-Basic vector (Promega). The sequences of PCR primers are: 5'-GTC ACT GGT ACC TCG AAA CTG TCC CAG AGA CG-3' and 5'-CGT TCC TCT GGT GGT GCT CTG CCT CAG-3'. The site-directed mutagenesis was performed by double PCR strategy. The PCR primers to mutate ETS-1 site are: 5'-CAG GTC TGA CCC TGG CAC AGG GTC AGT TCA GAC CTG-3'. The PCR primers to mutate ETS-2 site are: 5'-GCC TGA GCG CCC TGG CAC AGG GTC ACT GGT ACC TCG AAA CTG TCC CAG AGA CG-3' and 5'-CGT TCC TCT GGT GGT GCT CTG CCT CAG-3'.

Quantitative real time PCR (qPCR)

miRNA levels were determined by SYBR RT-qPCR. The first strand was synthesized using Mir-X™ miRNA First-Strand Synthesis Kit (Clontech, Palo Alto, CA, USA) according to the manufacturer’s instructions. The sequences of miRNA-specific qPCR primers are as follows: 5'-TAA TAC TGC CTG GTA ATG ATG A-3 (miR-200b); 5'-TAA TAC TGC CTG GTA ATG ATG A-3 (miR200a); 5'-TAA TAC TGC CTG GTA ATG ATG A-3 (hsa-miR-429); 5'-TAA TAC TGC CTG GTA ATG ATG A-3 (mmu-miR-429); 5'-TCC TTC ATT CCA CCG GAG TGT CTG-3' (miR-205). RNU48 was used as an internal control for comparing miRNA expression levels across different PCa cell lines. U6 snRNA served as an internal control for PC3 stable cell lines that express exogenous miRNAs. Reverse transcribed miRNAs were analyzed by real-time PCR using Sensi FAST SYBR green (Bioline).

Western blot analysis and antibodies

Rabbit anti-ERG monoclonal antibody (EPR3864, Abcam Inc. Cambridge, MA) and mouse anti-GAPDH monoclonal antibody (sc-32233, Santa Cruz Biotechnology) were used for western blot analysis. Rabbit anti-ERG polyclonal antibody (sc-354, Santa Cruz Biotechnology) was used for Chromatin Immunoprecipitation (ChIP) assay. Western blot analysis was using standard procedures.

ChIP assay

VCaP cells were cultured in DMEM high glucose media supplemented with 10% FBS and 1 mM R1881. The ChIP-IT Express kit (Active Motif) was used to perform the assay following the manufacturer’s protocol. Briefly, 1.5 × 10^7 cells were cross-linked in fixation solution and lysed to release the nuclei. Chromatin released from the nuclei was sonicated. The supernatant containing the sheared chromatin was used in immunoprecipitation. 5 µg of anti-ERG rabbit polyclonal antibody (sc-354, Santa Cruz Biotechnology) or control normal rabbit IgG (sc-2027, Santa Cruz Biotechnology) were added to chromatin and incubated overnight at 4°C. The immune complexes were collected using protein A-agarose beads, followed by extensive washing. The chromatin DNA-protein-antibody complexes were eluted and DNA-protein formaldehyde cross-links were reversed. The DNA fragments were purified by using a QIAquick PCR purification kit (QIAGEN) and analyzed by real-time PCR using SensiFAST SYBR green (Bioline). The PCR primers used for amplification of ERG binding region of miR-200b/a-429 promoter are: 5'-CCA CCT GTG CAG TGT CTG CCT CAG-3' and 5'-CTG CAA GGG TGA GCT TCC-3'.

Cancer cell proliferation and invasion assay

Cell proliferation was measured by using MTS assay. Briefly, PC3 stable cells were seeded at a density of 4 × 10^3 cells per well in flat-bottomed 96-well plates (day 0) and their growth was measured on days 3. Cell media were changed once on day 2. CellTiter 96 Aqueous One Solution Reagent (Promega) was added to each well. After 1 hr incubation, the cell viability was measured by determining the absorbance at 490 nM using the Multiskan FC microplate photometer (Thermo Scientific). The Matrigel invasion assay was performed using the BD Biocoat Matrigel Invasion Chamber (BD Biosciences) following the manufacturer’s instructions, and the pictures were taken using the EVOS XL Cell Imaging system (ThermoFisher).

Transgenic mice

The prostate-specific ERG overexpression transgenic mice (Pbsn-ERG) were purchased from Jackson Laboratories, strain name: STOCK Tg(Pbsn-ERG*)1Vv/J, and was previously reported [42]. The mice were housed in a temperature-controlled animal facility at Baylor College of Medicine with a 12-hr light, 12-hr dark photocycle and provided water and rodent chow meal ad libitum.

Statistical analysis

Student’s t-test was used for statistical analyses. A p-value cutoff of 0.05 was used to determine significance.

ACKNOWLEDGMENTS

We would like to thank Ms. Tanyalon Monroe for editing the manuscript. We also thank the Tissue Culture Core of Molecular and Cellular Biology Department and
Genetically Engineered Mouse Core for their assistance (P30CA125123).

CONFLICTS OF INTEREST
The authors declare no conflicts of interest.

GRANT SUPPORT
This work has been supported by NIH K01DK081446 (B.H.), American Cancer Society RSG-13-061-01-TBE (B.H.), Department of Defense BC122115 (Q.F.), NIH R21AI122418 (Q.F.), CNHPR (Q.F.), NIH K01DK096093 (S.M.H.), NIH R03DK105006 (S.M.H.), American Heart Association Beginning Grant-in-Aid 15BGIA25850025 (S.M.H.), and Dan L. Duncan Cancer (P30 CA125123) supporting Human Tissue Acquisition and Pathology (M.I.).

REFERENCES
1. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007; 26:2799–2803.
2. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Hemann MT, Hernando-Monge E, O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Thomson JM, Murphree AL, Li Z, Gomez MF, Lund E, Eisenberg R, Li M, Wang Y, Zheng Z, Maitra A, Menendes AC, Elledge SJ, congratulated by H. Milton. miR-21 targets the tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008; 27:2128–2136.
3. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008; 283:1026–1033.
4. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. A polycistronic microRNA cluster, miR-17–92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005; 65:9628–9632.
5. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435:828–833.
6. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435:839–843.
7. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proceedings of the National Proc Natl Acad Sci U S A. 2005; 102:3627–3632.
8. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005; 207:243–249.
9. Akao Y, Nakagawa Y, Naoe T. Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull. 2006; 29:903–906.
10. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aitier H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99:15524–15529.
11. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102:13944–13949.
12. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007; 17:1298–1307.
13. He L, He X, Lim LP, de Stanchina E, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447:1130–1134.
14. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26:745–752.
15. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007; 26:731–743.
16. Tarasov V, Jung P, Verdoord B, Lodygin D, Eparchintsev A, Menssen A, Meister G, Heremeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007; 6:1586–1593.
17. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell. 2005; 120:635–647.
18. Kim HH, Kuwano Y, Srikantan S, Lee DK, Martindale JL, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev. 2009; 23:1743–1748.
19. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmgaa2 enhances oncogenic transformation. Science. 2007; 315:1576–1579.
20. Kolesnikoff N, Attema JL, Roslan S, Bert AG, Schwarz QP, Gregory PA, Goodall GJ. Specificity protein 1 (Sp1) maintains basal epithelial expression of the miR-200 family: implications for epithelial-mesenchymal transition. J Biol Chem. 2014; 289:11194–11205.
21. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10:593–601.
22. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008; 22:894–907.

23. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna M, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9:582–589.

24. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283:14910–14914.

25. Bracken CP, Li X, Wright JA, Lawrence DM, Pillman KA, Salamandis M, Anderson MA, Dredge BK, Gregory PA, Tsykin A, Neilson C, Thomson DW, Bert AG, et al. Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion. EMBO J. 2014; 33:2040–2056.

26. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.

27. Song F, Yang D, Liu B, Guo Y, Zheng H, Li L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, et al. Integrated microRNA networks analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res. 2014; 20:878–889.

28. Diaz T, Tejero R, Moreno I, Ferrer G, Cordeiro A, Artells R, Navarro A, Hernandez R, Tapia G, Monzo M. Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J Surg Oncol. 2014; 109:676–683.

29. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009; 114:457–459.

30. Greene SB, Gunaratne PH, Hammond SM, Rosen JM. A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci. 2010; 123:606–618.

31. Zhang L, Zhao W, Valdez JM, Creighton CJ, Xin L. Low-density Taqman miRNA array reveals miRNAs differentially expressed in prostatic stem cells and luminal cells. Prostate. 2010; 70:297–304.

32. Greene SB, Herschkowitz JI, Rosen JM. The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol. 2010; 7:300–304.

33. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009; 69:2287–2295.

34. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310:644–648.

35. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010; 17:443–454.

36. Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng NY, Cheung E. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. Embo J. 2012; 31:2810–2823.

37. Chen Y, Chi P, Rockowizs S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongsipat J, Scher HI, Zheng D, Sawyers CL. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med. 2013; 19:1023–1029.

38. King JC, Xu J, Wongsipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL. Cooperativeity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009; 41:524–526.

39. Carver BS, Tran J, Gopalanan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41:619–624.

40. Taylor BS, Schultz N, Hieronymus H, Gopalanan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18:11–22.

41. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, Yan J, Taluukder S, Turunen M, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 2010; 29:2147–2160.

42. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A. 2008; 105:2105–2110.

43. Kim J, Wu L, Zhao JC, Jin HJ, Yu J. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene. 2014; 33:5183–5192.

44. Culig Z. Words of wisdom: Re: TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Eur Urol. 2014; 65:1011.
45. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vosden KH, Muller PA, Dotsch V, Kehrloesser S, Sayan BS, Giaccone G, Lowe SW, Takahashi N, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 2012; 109:15312–15317.

46. Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan C, He X, Sood AK, Zhang X, Lu X. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell Rep. 2014; 8:1447–1460.

47. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008; 14:3395–3400.

48. Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res. 2009; 15:6398–6403.

49. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, et al. TMPRSS2:ERG fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26:4596–4599.

50. Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Oyan AM, Haese A, Budaas L, Albrecht H, Akslen LA, Schlomm T, Kalland KH. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26:4596–4599.

51. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M. TMPRSS2:ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2011; 71:489–497.

52. Rawal S, Young D, Williams M, Colombo M, Krishnappa R, Petrovics G, McLeod DG, Sesterhenn IA, Srivastava S. Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India. J Cancer. 2013; 4:468–472.